Compare COR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COR | ARGX |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | Netherlands |
| Employees | 51000 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1B | 58.4B |
| IPO Year | 2001 | 2017 |
| Metric | COR | ARGX |
|---|---|---|
| Price | $306.31 | $958.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $390.62 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 1.0M | 204.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 5.71 | N/A |
| EPS | ★ 15.21 | N/A |
| Revenue | ★ $321,332,819,000.00 | N/A |
| Revenue This Year | $8.89 | $44.39 |
| Revenue Next Year | $6.75 | $20.84 |
| P/E Ratio | ★ $20.37 | $33.69 |
| Revenue Growth | ★ 9.31 | N/A |
| 52 Week Low | $244.82 | $661.85 |
| 52 Week High | $377.54 | $1,072.75 |
| Indicator | COR | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 44.84 |
| Support Level | $299.49 | $836.30 |
| Resistance Level | $312.18 | $1,072.75 |
| Average True Range (ATR) | 7.24 | 19.61 |
| MACD | -2.14 | -9.56 |
| Stochastic Oscillator | 9.50 | 31.66 |
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.